Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Valentine Richez(Centre Hospitalier Universitaire de Nice), Xavier Leleu(Inserm), Delphine Bauwens(Centre Hospitalier Universitaire de Poitiers), Niels Moya(Inserm), Cécile Gruchet(Inserm), Vincent Javaugue(Université de Poitiers), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), C. Diéval(Centre Hospitalier de Rochefort), Stéphanie Guidez(Inserm), I Azaïs(Centre Hospitalier Universitaire de Poitiers), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Arthur Bobin(Inserm), Antoine Machet(Inserm), Emmanuel Fleck(Centre Hospitalier de La Rochelle), Florence Sabirou(Inserm), Frank Bridoux(Université de Poitiers), G. Durand(Centre Hospitalier Universitaire de Poitiers), Isabelle Princet(Centre Hospitalier Universitaire de Poitiers), Anthony Lévy(Inserm), Antoine Brigaud(Centre Hospitalier d'Angoulême)
Cited by 2
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906